Equities

DNA Chip Research Inc

2397:TYO

DNA Chip Research Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)701.00
  • Today's Change-1.00 / -0.14%
  • Shares traded14.60k
  • 1 Year change-1.96%
  • Beta1.9366
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments388275489
Total Receivables, Net190206173
Total Inventory68188.06
Prepaid expenses142037
Other current assets, total175.962.86
Total current assets677525710
Property, plant & equipment, net1081142.44
Goodwill, net------
Intangibles, net139164142
Long term investments000
Note receivable - long term------
Other long term assets596035
Total assets982871890
LIABILITIES
Accounts payable705547
Accrued expenses342631
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total1054021
Total current liabilities20912199
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total413910
Total liabilities250160110
SHAREHOLDERS EQUITY
Common stock927792642
Additional paid-in capital955820670
Retained earnings (accumulated deficit)(1150)(902)(532)
Treasury stock - common(0.09)(0.09)(0.09)
Unrealized gain (loss)------
Other equity, total----0.00
Total equity732711781
Total liabilities & shareholders' equity982871890
Total common shares outstanding6.766.355.79
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.